A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) [beta]-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer

• Published in: Cancer biotherapy & radiopharmaceuticals Vol. 32; no. 2; p. 57
• Main Authors: Revskaya, Ekaterina, Jiang, Zewei, Morgenstern, Alfred, Bruchertseifer, Frank, Sesay, Muctarr, Walker, Susan, Fuller, Steven, Lebowitz, Michael S, Gravekamp, Claudia, Ghanbari, Hossein A, Dadachova, Ekaterina
• Format: Journal Article
• Language: English
• Published: New Rochelle Mary Ann Liebert, Inc 01.03.2017
• ISSN: 1084-9785; 1557-8852
• DOI: 10.1089/cbr.2016.2141

There is a need for novel effective and safe therapies for metastatic breast cancer based on targeting tumor-specific molecular markers of cancer. Human aspartyl (asparaginyl) β-hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins and is overexpressed in a variety of cancers, including breast cancer. A fully human monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and radioimmunotherapy of metastatic breast cancer. PAN-622 was conjugated to several ligands such as DOTA, CHXA'', and DTPA to enable subsequent radiolabeling and its immunoreactivity was evaluated by an HAAH-specific enzyme-linked immunosorbent assay and binding to the HAAH-positive cells. As a result, DTPA-PAN-622 was chosen to investigate biodistribution in healthy CD-1 female mice and 4T1 mammary tumor-bearing BALB/c mice. The [sup]111In-DTPA-pan622 mAb concentrated in the primary tumors and to some degree in lung metastases as shown by SPECT/CT and Cherenkov imaging. A pilot therapy study with [sup]213Bi--DTPA-PAN-622 demonstrated a significant effect on the primary tumor. The authors concluded that human mAb PAN-622 to HAAH is a promising reagent for development of imaging and possible therapeutic agents for the treatment of metastatic breast cancer.